Krystal Biotech (NASDAQ:KRYS) has received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use for approval of its drug Vyjuvek for the treatment of wounds in certain patients with dystrophic epidermolysis bullosa, or DEB.